An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.

ABSTRACT: Androgen deprivation therapy (ADT) is the main treatment approach in advanced prostate cancer and in recent years has primarily involved the use of gonadotropin-releasing hormone (GnRH) agonists. However, despite their efficacy, GnRH agonists have several drawbacks associated with their mode of action. These include an initial testosterone surge and testosterone microsurges on repeat administration. GnRH antagonists provide an alternative approach to ADT with a more direct mode of action that involves immediate blockade of GnRH receptors. Antagonists produce a more rapid suppression of testosterone (and prostate-specific antigen [PSA]) without a testosterone surge or microsurges and appear to offer an effective and well tolerated option for the hormonal treatment of prostate cancer. Compar

SUBMITTER: Boccon-Gibod L 

PROVIDER: S-EPMC3159401 | biostudies-literature | 2011 Jun

REPOSITORIES: biostudies-literature